-
Something wrong with this record ?
Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012
H. Orlíková, M. Malý, P. Lexová, H. Šebestová, R. Limberková, L. Jurzykowská, J. Kynčl,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT14059
MZ0
CEP Register
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
Public Health Database (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Time Factors MeSH
- Child MeSH
- Adult MeSH
- Encephalitis epidemiology prevention & control MeSH
- Hospitalization statistics & numerical data MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Meningitis epidemiology prevention & control MeSH
- Adolescent MeSH
- Young Adult MeSH
- Infant, Newborn MeSH
- Immunization Schedule MeSH
- Orchitis epidemiology prevention & control MeSH
- Child, Preschool MeSH
- Mumps complications epidemiology prevention & control MeSH
- Risk MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Population Surveillance * MeSH
- Mumps Vaccine administration & dosage MeSH
- Vaccination statistics & numerical data MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
BACKGROUND: In the Czech Republic, two-dose immunization against mumps achieves 98% coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. METHODS: We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region, the association between vaccination and the most frequent mumps complications and hospitalization was evaluated. The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa) × 100. We estimated the risk of mumps complications by the time from vaccination. RESULTS: From total of 9663 mumps analysed cases 5600 (58%) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6% developed meningitis, 0.2% encephalitis, and 0.6% pancreatitis. Mumps orchitis occurred in 659 (11.8%) male cases. In total, 1192 (12.3%) patients required hospitalization. Two doses of vaccine received by 81.8% cases significantly reduced the risk of hospitalization: ORa 0.29 (95% CI: 0.24, 0.35). Two doses showed statistically significant VEa 64% (95% CI: 46, 79) for meningitis, 93% (95% CI: 66, 98) for encephalitis in all cases, and 72% (95% CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74% and 56% in the most affected age groups 10-14, 15-19, and 20-24 years, respectively. Among 7850 two-dose recipients, the rate of complications rose from below 1 to 16% in categories up to 6 years and 24 and more years after the second dose, respectively. CONCLUSIONS: This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000305
- 003
- CZ-PrNML
- 005
- 20181210090753.0
- 007
- ta
- 008
- 170103s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12889-016-2958-4 $2 doi
- 024 7_
- $a 10.1186/s12889-016-2958-4 $2 doi
- 035 __
- $a (PubMed)27036176
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Orlíková, Hana, $d 1965- $7 xx0218806 $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic. hana.orlikova@szu.cz.
- 245 10
- $a Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012 / $c H. Orlíková, M. Malý, P. Lexová, H. Šebestová, R. Limberková, L. Jurzykowská, J. Kynčl,
- 520 9_
- $a BACKGROUND: In the Czech Republic, two-dose immunization against mumps achieves 98% coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. METHODS: We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region, the association between vaccination and the most frequent mumps complications and hospitalization was evaluated. The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa) × 100. We estimated the risk of mumps complications by the time from vaccination. RESULTS: From total of 9663 mumps analysed cases 5600 (58%) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6% developed meningitis, 0.2% encephalitis, and 0.6% pancreatitis. Mumps orchitis occurred in 659 (11.8%) male cases. In total, 1192 (12.3%) patients required hospitalization. Two doses of vaccine received by 81.8% cases significantly reduced the risk of hospitalization: ORa 0.29 (95% CI: 0.24, 0.35). Two doses showed statistically significant VEa 64% (95% CI: 46, 79) for meningitis, 93% (95% CI: 66, 98) for encephalitis in all cases, and 72% (95% CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74% and 56% in the most affected age groups 10-14, 15-19, and 20-24 years, respectively. Among 7850 two-dose recipients, the rate of complications rose from below 1 to 16% in categories up to 6 years and 24 and more years after the second dose, respectively. CONCLUSIONS: This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a Česká republika $x epidemiologie $7 D018153
- 650 _2
- $a encefalitida $x epidemiologie $x prevence a kontrola $7 D004660
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hospitalizace $x statistika a číselné údaje $7 D006760
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a očkovací schéma $7 D007115
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a meningitida $x epidemiologie $x prevence a kontrola $7 D008581
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a příušnice $x komplikace $x epidemiologie $x prevence a kontrola $7 D009107
- 650 _2
- $a vakcína proti příušnicím $x aplikace a dávkování $7 D009108
- 650 _2
- $a orchitida $x epidemiologie $x prevence a kontrola $7 D009920
- 650 12
- $a surveillance populace $7 D011159
- 650 _2
- $a riziko $7 D012306
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a vakcinace $x statistika a číselné údaje $7 D014611
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Malý, Marek $u Department of Biostatistics, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
- 700 1_
- $a Lexová, Pavla $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
- 700 1_
- $a Šebestová, Helena $u Department of Biostatistics, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
- 700 1_
- $a Limberková, Radomíra $u National Reference Laboratory for Measles, Mumps, Rubella and Parvovirus B19, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
- 700 1_
- $a Jurzykowská, Lucie $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
- 700 1_
- $a Kynčl, Jan $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic. Department of Epidemiology, 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 10000, Prague, Czech Republic.
- 773 0_
- $w MED00008205 $t BMC public health $x 1471-2458 $g Roč. 16, č. - (2016), s. 293
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27036176 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20181210090914 $b ABA008
- 999 __
- $a ok $b bmc $g 1179445 $s 960872
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 16 $c - $d 293 $e 20160401 $i 1471-2458 $m BMC public health $n BMC Public Health $x MED00008205
- GRA __
- $a NT14059 $p MZ0
- LZP __
- $a Pubmed-20170103